|View printer-friendly version|
Showcasing Scientific Excellence
Throughout the conference, Charles River experts will be presenting posters and hosting discussions on the latest innovations in neuroscience research, including innovative tools and applications for research on drugs targeting Huntington’s, Alzheimer’s, Parkinson’s, Multiple Sclerosis, and other neurological disorders.
Noteworthy posters include:
Assay development and validation of a high content-based
high-throughput assay to measure α-synuclein aggregation in
dopaminergic human neurons differentiated in vitro (Presented:
Sunday, November 12, 2:00 p.m. to 3:00 p.m.) This study, with the Michael J. Fox Foundation, describes an assay that can be used to test drugs for Parkinson’s disease.
Results of a phenotypic HTS to identify small molecule modulators
of mutant HTT levels in hES cells as HD therapies (Presented:
Monday, November 13, 1:00 p.m. to 5:00 p.m.) This study, presented in conjunction with CHDI Foundation, used stem cells with the Huntington’s disease mutation to create a high-throughput screen for compounds that decrease levels of the mutant protein that causes the disease.
Deficits in Touchscreen-based Operant Tasks and Fear Conditioning
Memory in the Cuprizone Model of Multiple Sclerosis (Presented:
Monday, November 13, 8:00 a.m. to 9:00 a.m.) Leveraging touchscreen technology, this study tested cognitive function and memory in mice with an MS-like condition.
During the conference, Charles River will host short discussion sessions in Booth #1115, covering topics including profiling ion channels, PET imaging in neuroinflammation, and the use of CRISPR in neuroscience drug discovery.
Expanded Neuroscience Capabilities
In August, Charles River announced
the acquisition of Brains On-Line, a neuroscience-focused provider
of microdialysis and in vivo efficacy and pharmacokinetics
testing. Together, Brains On-Line and Charles River are a premier
early-stage research and development partner for neuroscience drug
discovery. During Neuroscience 2017, visit the Brains On-Line, a
Supporting Neuroscience Research
Over the years, Charles River has donated to research organizations to
help advance novel drug discoveries. To continue that support at
Neuroscience 2017, Charles River encourages conference attendees to
“walk” their way to funding critical research. The Company will give
away pedometers at Booth #1115 during the conference, with each
participant’s step totals driving Charles River’s donation to the
A full schedule of Charles River’s activities during Neuroscience 2017 is available online, and reprints of each poster are available in Booths #1115 and #935 during the conference. Additionally, experts are available for meetings with those interested in discussing neuroscience research and drug discovery. Throughout the conference, Charles River will be providing live updates on the Eureka Blog, including reviews of scientific sessions and input on the research being presented.
- “Our scientists are exploring groundbreaking science in the treatment of Alzheimer’s, MS, and Parkinson’s; therapeutic areas that significantly impact the lives of millions. Neuroscience 2017 provides our scientists an important opportunity to share their research and collaborate with peers from across the globe.” –Birgit Girshick, Corporate Senior Vice President, Global Discovery Services, Charles River
- “The field of neuroscience is constantly progressing, with new technologies and discoveries being announced every day. We’re extremely proud of the body of work we’re presenting this year, and look forward to leveraging what we learn at Neuroscience 2017 to advance our research.” –Antti Nurmi, PhD, Managing Director, Charles River Discovery Services
- “Neuroscience has been one of the most challenging areas of drug discovery, but the adoption of innovative technologies like CRISPR and increasingly, translational model systems and biomarkers, is opening up new opportunities in this fast-paced field.” –Ian Waddell, PhD, Executive Director of Biology, Charles River Discovery Services
- “This year, Charles River is supporting SfN by promoting the simplest of activities: walking. Together we create healthier lives—through our research, our support of critically important foundations, and our actions.” –William Barbo, Executive Vice President & Chief Commercial Officer, Charles River
About the Society for Neuroscience
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
Charles River Laboratories International, Inc.
Susan E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
Amy Cianciaruso, 781-222-6168
Corporate Vice President, Public Relations